Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.64 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.64 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.50 |
| ▸ | DGKA | P23743 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | PAM | P19021 | 2/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.42 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.42 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | FNTA | P49354 | 1/20 | 0.41 |
| ▸ | FNTB | P49356 | 1/20 | 0.41 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8737410 | 1.00 | GPR84 (0.64) | GPR84FFAR1FFAR4ALDH1A1CAMK2A | |
| SCHEMBL8679037 | 1.00 | GPR84 (0.64) | GPR84FFAR1FFAR4ALDH1A1CAMK2A | |
| SCHEMBL6397493 | 1.00 | GPR84 (0.64) | GPR84FFAR1FFAR4ALDH1A1CAMK2A | |
| SCHEMBL3505305 | 1.00 | GPR84 (0.64) | GPR84FFAR1FFAR4ALDH1A1CAMK2A | |
| SCHEMBL21114449 | 1.00 | GPR84 (0.64) | GPR84FFAR1FFAR4ALDH1A1CAMK2A | |
| SCHEMBL7606824 | 1.00 | GPR84 (0.64) | GPR84FFAR1FFAR4ALDH1A1CAMK2A | |
| SCHEMBL7033618 | 1.00 | GPR84 (0.64) | GPR84FFAR1FFAR4ALDH1A1CAMK2A | |
| SCHEMBL18710354 | 1.00 | GPR84 (0.64) | GPR84FFAR1FFAR4ALDH1A1CAMK2A | |
| SCHEMBL12922833 | 1.00 | GPR84 (0.64) | GPR84FFAR1FFAR4ALDH1A1CAMK2A | |
| SCHEMBL2376184 | 1.00 | GPR84 (0.64) | GPR84FFAR1FFAR4ALDH1A1CAMK2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030069232-A1 | Topical treatment of ocular hypertension, glaucoma, ischemic retinopathy and age-related macular degeneration with ophthalmic formulation of dopamine antagonists | CHIOU GEORGE C Y (US) | 2003-04-10 | — | — | US | claimed |
| EP-1225879-A2 | OPHTHALMIC FORMULATION OF DOPAMINE ANTAGONISTS | Orbon Corporation (US) | 2002-07-31 | — | — | EP | claimed |
| WO-2001030337-A2 | OPHTHALMIC FORMULATION OF DOPAMINE ANTAGONISTS | ORBON CORPORATION (US) | 2001-05-03 | — | — | WO | claimed |
| US-5962526-A | ENHANCING THERAPEUTIC EFFECT OT TOPICALLY APPLIED AGENTS | TRISTRATA TECHNOLOGY, INC. (US) | 1999-10-05 | — | — | US | claimed |
| US-20030069232-A1 | Topical treatment of ocular hypertension, glaucoma, ischemic retinopathy and age-related macular degeneration with ophthalmic formulation of dopamine antagonists | CHIOU GEORGE C Y (US) | 2003-04-10 | — | — | US | disclosed |
| EP-1225879-A2 | OPHTHALMIC FORMULATION OF DOPAMINE ANTAGONISTS | Orbon Corporation (US) | 2002-07-31 | — | — | EP | disclosed |
| WO-2001030337-A2 | OPHTHALMIC FORMULATION OF DOPAMINE ANTAGONISTS | ORBON CORPORATION (US) | 2001-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069232-A1 | Topical treatment of ocular hypertension, glaucoma, ischemic retinopathy and age-related macular degeneration with ophthalmic formulation of dopamine antagonists | ALDH1A2, SLC6A3, PINK1 | GPR84 881/4885FFAR1 317/4885FFAR4 790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.